- Home
- VEL vs IMTX Comparison
VEL vs IMTX Comparison
Compare VEL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- IMTX
- Stock Information
- Founded
- VEL 2004
- IMTX N/A
- Country
- VEL United States
- IMTX Germany
- Employees
- VEL N/A
- IMTX N/A
- Industry
- VEL Finance: Consumer Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VEL Finance
- IMTX Health Care
- Exchange
- VEL Nasdaq
- IMTX Nasdaq
- Market Cap
- VEL 680.6M
- IMTX 579.8M
- IPO Year
- VEL 2020
- IMTX N/A
- Fundamental
- Price
- VEL $18.73
- IMTX $5.52
- Analyst Decision
- VEL Buy
- IMTX Strong Buy
- Analyst Count
- VEL 5
- IMTX 4
- Target Price
- VEL $21.20
- IMTX $14.67
- AVG Volume (30 Days)
- VEL 202.3K
- IMTX 816.9K
- Earning Date
- VEL 07-31-2025
- IMTX 08-12-2025
- Dividend Yield
- VEL N/A
- IMTX N/A
- EPS Growth
- VEL 14.80
- IMTX N/A
- EPS
- VEL 1.94
- IMTX N/A
- Revenue
- VEL $177,987,000.00
- IMTX $155,801,989.00
- Revenue This Year
- VEL N/A
- IMTX N/A
- Revenue Next Year
- VEL $32.82
- IMTX $1.92
- P/E Ratio
- VEL $9.55
- IMTX N/A
- Revenue Growth
- VEL 39.36
- IMTX 93.56
- 52 Week Low
- VEL $16.12
- IMTX $3.30
- 52 Week High
- VEL $20.98
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- VEL 58.00
- IMTX 49.74
- Support Level
- VEL $18.46
- IMTX $5.23
- Resistance Level
- VEL $19.00
- IMTX $5.71
- Average True Range (ATR)
- VEL 0.42
- IMTX 0.29
- MACD
- VEL -0.04
- IMTX -0.08
- Stochastic Oscillator
- VEL 21.95
- IMTX 25.22
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.